PE1698A1 - Nuevo proceso para la produccion de una sal acida calcica amorfa [r- (r ,r )]-2-(4-fluorofenilo)-�-�-dihidroxi-5-(1-metiletilo)-3-fenilo-4-[(fenilamino)carbonilo]-1h-pirrol-1-acido heptanoico - Google Patents

Nuevo proceso para la produccion de una sal acida calcica amorfa [r- (r ,r )]-2-(4-fluorofenilo)-�-�-dihidroxi-5-(1-metiletilo)-3-fenilo-4-[(fenilamino)carbonilo]-1h-pirrol-1-acido heptanoico

Info

Publication number
PE1698A1
PE1698A1 PE1996000541A PE00054196A PE1698A1 PE 1698 A1 PE1698 A1 PE 1698A1 PE 1996000541 A PE1996000541 A PE 1996000541A PE 00054196 A PE00054196 A PE 00054196A PE 1698 A1 PE1698 A1 PE 1698A1
Authority
PE
Peru
Prior art keywords
calcica
pirrol
phenylamine
methylethyl
fluorophenyl
Prior art date
Application number
PE1996000541A
Other languages
English (en)
Inventor
Min Lin
Dieter Schweiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE1698(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE1698A1 publication Critical patent/PE1698A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

SE REFIERE AL PROCESO DE PREPARACION DE LA ATORVASTATINA AMORFA, QUE COMPRENDE: A) LA DISOLUCION DE LA FORMA (I) DE ATORVASTATINA CRISTALINA EN UN SOLVENTE NO HIDROXILICO TAL COMO TETRAHIDROFURANO (THF) O MEZCLAS DE THF Y TOLUENO; B) LA REMOCION DEL SOLVENTE PARA LOGRAR LA ATORVASTATINA AMORFA MEDIANTE: 1) SECADO AL SPRAY, O PREFERENTEMENTE 2) DESECACION A VACIO (DE 5 mmHg A 25 mmHg): A UNA TEMPERATURA INICIAL DE 35�C Y A UNA TEMPERATURA SUBSECUENTE DE 85�C;Y C) AGITACION MECANICA PARA SEPARAR LA ESPUMA BRILLANTE OBTENIDA. LA FORMA AMORFA PRESENTA UN MODELO DE BIODISPONIBILIDAD FAVORABLE EN ALGUNAS INDICACIONES TERAPEUTICAS, POR LO QUE ESTE PROCESO RESULTA ADECUADO EN SU OBTENCION A ESCALA INDUSTRIAL
PE1996000541A 1995-07-17 1996-07-17 Nuevo proceso para la produccion de una sal acida calcica amorfa [r- (r ,r )]-2-(4-fluorofenilo)-�-�-dihidroxi-5-(1-metiletilo)-3-fenilo-4-[(fenilamino)carbonilo]-1h-pirrol-1-acido heptanoico PE1698A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17

Publications (1)

Publication Number Publication Date
PE1698A1 true PE1698A1 (es) 1998-02-19

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000541A PE1698A1 (es) 1995-07-17 1996-07-17 Nuevo proceso para la produccion de una sal acida calcica amorfa [r- (r ,r )]-2-(4-fluorofenilo)-�-�-dihidroxi-5-(1-metiletilo)-3-fenilo-4-[(fenilamino)carbonilo]-1h-pirrol-1-acido heptanoico

Country Status (38)

Country Link
US (1) US6274740B1 (es)
EP (1) EP0839132B1 (es)
JP (1) JP4064459B2 (es)
KR (1) KR100400805B1 (es)
CN (1) CN1087289C (es)
AR (1) AR002849A1 (es)
AT (1) ATE199542T1 (es)
AU (1) AU700794B2 (es)
BG (1) BG63631B1 (es)
BR (1) BR9609714A (es)
CA (1) CA2220455C (es)
CO (1) CO4700441A1 (es)
CZ (1) CZ289421B6 (es)
DE (1) DE69611999T2 (es)
DK (1) DK0839132T5 (es)
EA (1) EA000625B1 (es)
EE (1) EE03605B1 (es)
ES (1) ES2156997T3 (es)
GE (1) GEP20002027B (es)
GR (1) GR3035859T3 (es)
HK (1) HK1018054A1 (es)
HR (1) HRP960312B1 (es)
HU (1) HU220343B (es)
IL (1) IL122161A (es)
IN (1) IN185276B (es)
MX (1) MX9708959A (es)
NO (1) NO309322B1 (es)
NZ (1) NZ313008A (es)
PE (1) PE1698A1 (es)
PL (1) PL191017B1 (es)
PT (1) PT839132E (es)
RO (1) RO120069B1 (es)
SI (1) SI0839132T1 (es)
SK (1) SK283204B6 (es)
UA (1) UA50743C2 (es)
UY (1) UY24286A1 (es)
WO (1) WO1997003960A1 (es)
ZA (1) ZA966043B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IN191236B (es) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
EP1341785B1 (en) 2000-11-16 2008-10-08 Teva Pharmaceutical Industries Ltd. Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
EP1345896B1 (en) 2000-12-27 2009-01-07 Teva Pharmaceutical Industries Limited Crystalline forms of atorvastatin
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (es) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
PL367943A1 (en) 2001-06-29 2005-03-07 Warner-Lambert Company Llc Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
CA2456095C (en) 2001-08-31 2010-05-11 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
WO2003078379A1 (en) 2002-03-18 2003-09-25 Biocon Limited AMORPHOUS Hmg-CoA REDUCTASE INHIBITORS OF DESIRED PARTICLE SIZE
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
EP1562583A1 (en) * 2002-09-03 2005-08-17 Morepen Laboratories Ltd. Atorvastatin calcium form vi or hydrates thereof
WO2004089895A1 (en) * 2003-04-11 2004-10-21 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
WO2004094343A1 (en) 2003-04-22 2004-11-04 Biocon Limited NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ß-KETOESTERS
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
AU2003272080A1 (en) 2003-09-18 2005-04-06 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
US7994343B2 (en) * 2004-03-17 2011-08-09 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
JP2008510798A (ja) 2004-08-27 2008-04-10 バイオコン・リミテッド 非晶質アトルバスタチンカルシウムのための方法
WO2006039441A2 (en) * 2004-09-30 2006-04-13 Dr. Reddy's Laboratories Ltd. Amorphous atorvastatin calcium
US20060106230A1 (en) * 2004-10-18 2006-05-18 Michael Pinchasov Processes for preparing amorphous atorvastatin hemi-calcium
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
EP1814541A4 (en) 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd STABLE ATORVASTATIN FORMULATIONS
WO2006059224A1 (en) * 2004-12-02 2006-06-08 Warner-Lambert Company Llc Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
KR20070116963A (ko) * 2006-03-01 2007-12-11 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미 칼슘 결정형의 제조 방법
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
EP2373609B1 (en) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
RO120070B1 (ro) 1995-07-17 2005-08-30 Warner-Lambert Company Forme cristaline ale sării semicalcice a acidului| [(r-(r*, r*)]-2-(4-fluorofenil)-beta-delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)carbonil]-1h-pirol-1-heptanoic (atorvastatin)

Also Published As

Publication number Publication date
ZA966043B (en) 1997-02-03
NO980209L (no) 1998-01-16
SK283204B6 (sk) 2003-03-04
WO1997003960A1 (en) 1997-02-06
DK0839132T5 (da) 2006-03-20
DE69611999T2 (de) 2001-07-26
EA199800128A1 (ru) 1998-08-27
AU700794B2 (en) 1999-01-14
CN1087289C (zh) 2002-07-10
AU6497896A (en) 1997-02-18
PL191017B1 (pl) 2006-03-31
HRP960312A2 (en) 1998-02-28
IN185276B (es) 2000-12-16
ES2156997T3 (es) 2001-08-01
PL324463A1 (en) 1998-05-25
BG63631B1 (bg) 2002-07-31
BG102188A (en) 1998-08-31
CO4700441A1 (es) 1998-12-29
NZ313008A (en) 2000-01-28
US6274740B1 (en) 2001-08-14
UA50743C2 (uk) 2002-11-15
IL122161A0 (en) 1998-04-05
DE69611999D1 (de) 2001-04-12
CA2220455A1 (en) 1997-02-06
EP0839132A1 (en) 1998-05-06
ATE199542T1 (de) 2001-03-15
CZ289421B6 (cs) 2002-01-16
AR002849A1 (es) 1998-04-29
CA2220455C (en) 2002-09-24
BR9609714A (pt) 1999-02-23
HUP9903017A3 (en) 2001-01-29
EE03605B1 (et) 2002-02-15
EA000625B1 (ru) 1999-12-29
JP4064459B2 (ja) 2008-03-19
IL122161A (en) 1999-07-14
GEP20002027B (en) 2000-04-10
SK5898A3 (en) 1998-08-05
KR19990029045A (ko) 1999-04-15
UY24286A1 (es) 1997-01-17
KR100400805B1 (ko) 2003-12-24
EE9700369A (et) 1998-06-15
PT839132E (pt) 2001-06-29
SI0839132T1 (es) 2001-06-30
HU220343B (hu) 2001-12-28
MX9708959A (es) 1998-03-31
RO120069B1 (ro) 2005-08-30
EP0839132B1 (en) 2001-03-07
NO980209D0 (no) 1998-01-16
HK1018054A1 (en) 1999-12-10
GR3035859T3 (en) 2001-08-31
NO309322B1 (no) 2001-01-15
HRP960312B1 (en) 2001-10-31
JPH11510486A (ja) 1999-09-14
DK0839132T3 (da) 2001-04-09
CZ12298A3 (cs) 1998-12-16
CN1190956A (zh) 1998-08-19

Similar Documents

Publication Publication Date Title
PE1698A1 (es) Nuevo proceso para la produccion de una sal acida calcica amorfa [r- (r ,r )]-2-(4-fluorofenilo)-�-�-dihidroxi-5-(1-metiletilo)-3-fenilo-4-[(fenilamino)carbonilo]-1h-pirrol-1-acido heptanoico
ATE270661T1 (de) Verfahren zur herstellung von amorphem atorvastatin
BG102186A (en) Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
CA2188905A1 (en) Process for the preparation of dihaloazolopyrimidines
IT1235048B (it) Derivato di 4h-benzopiran-4-one o suo sale, procedimento per produrlo e composizione farmaceutica che lo contiene come ingrediente attivo
IL190905A0 (en) 4-alkoxy cyclohexane-1-amino carboxylic acids and processes for their prepatation
EP1679071A4 (en) COLLAGEN PRODUCTION AMPLIFIER AND MANUFACTURING METHOD AND USE
NO20060351L (no) Anvendelse av 2,2 dimetyl-3-(2,4-diklorfenyl)-2-okso-1-oksaspiro[4,5]dec-3-en-4-ylbutanoat for a bekjempe akkarider
MX2007004425A (es) Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
DE50113398D1 (de) Verfahren zur herstellung von n-methyl-n'-nitroguanidin
DE50207212D1 (de) Verfahren zur herstellung von 2-pyrrolidon
BR8503419A (pt) Processo para a preparacao de 5-amino-1-fenilpirazois substituidos,composicoes herbicidas,e processos para combater ervas daninhas e para a preparacao de azometinas
DE50203418D1 (de) Verfahren zur herstellung von pyrrolidonen
DK0820439T3 (da) Fremgangsmåde til asymmetrisk syntese af S-acylerede derivater af 2-mercaptomethyl-3-phenylpropansyre og anvendelse deraf t
DE50112690D1 (de) Verfahren zur aufbereitung von pyrrolidon- und n-vinylpyrrolidon-rückständen
CA2191893A1 (en) Process for the preparation of heterocyclic aldehydes
DE59409874D1 (de) Verfahren zur Herstellung von Pyrrolidin-Derivaten durch Pd-katalysierte Addition von Aminen an Vinyloxiranen
RU2001106982A (ru) Способ получения левулиновой кислоты
JPS5325560A (en) Preparation of 1-alkyl-2-aminoalkylpyrrolidine
JPS53144587A (en) Purification of aminopyrazinecarboxylic acid
UY26178A1 (es) Amidas de ácidos fenilciclohexanocarboxilicos sustituidos.
CH253182A (de) Verfahren zur Darstellung eines acylierten, aliphatischen Aminocarbonsäureamids.
RU98116406A (ru) Способ получения гамма-аминомасляной кислоты
TH18619EX (th) ไอโซควินโนลีน
RU2001106526A (ru) Средство для лечения ишемических поражений мозга

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term